KIR2DS2 (killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 ) Blocking Peptide (the N terminal of KIR2DS2)(100ug)

Supplier: Aviva Systems Biology Incorporated

0 reviews | Write a Review Pencil

Description
Additional Information

This is a synthetic peptide designed for use in combination with anti-KIR2DS2 Antibody (ARP63891_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Reactivities:	Human
Presku:	AAP63891
Size:	100ug
Weight:	32kDa
Gene:	100132285
Format:	Lyophilized powder
Target:	Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies among haplotypes, although several 'framework' genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase binding protein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules; thus, KIR proteins are thought to play an important role in regulation of the immune response.
Alternative names:	CU464060.1, 183ActI, CD158J, CD158b, NKAT5, cl-49